Intravenous Immunoglobulin Therapy Administered Early after Narcolepsy Type 1 Onset in Three Patients Evaluated by Clinical and Polysomnographic Follow-Up
Narcolepsy type 1 is a rare disabling sleep disorder mainly characterized by excessive daytime sleepiness and cataplexy, an emotion-triggered sudden loss of muscle tone. Patients have a selective degeneration of hypocretin-producing neurons in the dorsolateral posterior hypothalamus with growing evi...
Main Authors: | Elisabeth Ruppert, Hélène Zagala, Juliette Chambe, Henri Comtet, Ulker Kilic-Huck, François Lefebvre, Marc Bataillard, Carmen Schroder, Laurent Calvel, Patrice Bourgin |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2018-01-01
|
Series: | Behavioural Neurology |
Online Access: | http://dx.doi.org/10.1155/2018/1671072 |
Similar Items
-
Clinical and Polysomnographic Comparison between Narcolepsy without Cataplexy and Idiopathic Hypersomnia
by: Tae Won Kim, et al.
Published: (2012-10-01) -
Polysomnographic Assessment of Sleep Comorbidities in Drug-Naïve Narcolepsy-Spectrum Disorders--A Japanese Cross-Sectional Study.
by: Taeko Sasai-Sakuma, et al.
Published: (2015-01-01) -
Immunological and Genetic Aspects of Narcolepsy
by: Juliette Faraco, et al.
Published: (2011-08-01) -
Safety of Intravenous Immunoglobulin (Tegeline®), Administered at Home in Patients with Autoimmune Disease: Results of a French Study
by: Eric Hachulla, et al.
Published: (2018-01-01) -
Side Effects of Intravenous Immunoglobulin Treatment in Neurological Disorders
by: Buket Oflazoğlu, et al.
Published: (2006-02-01)